Published: 2021-06-01 16:14 | Updated: 2021-06-02 10:11

Current calls, week 22, 2021

Tips from Grants Office regarding current calls.

Swedish and Nordic calls

 

Research grant - Swedish Psoriasis Association

Supports scientific projects aimed at increasing knowledge about psoriasis and psoriatic arthritis.

Closing date: 15 June 2021

Further information 

 

Swedish Dental Association’s scientific funds Swedish Dental Association

Supports dental research and travel in connection with such research. Grants are worth between SEK 35,000 and SEK 100,000.

Closing date: 15 June 2021

Further information 
 

Leo foundation award – Europe, Middle East, Africa LEO Pharma Research Foundation

Recognises young scientists who have made important contributions within the field of dermatology research. The award is worth USD 100,000.

Closing date: 18 June 2021

Further information 

 

Research on LGBTQ+ people’s life situation and health  - Swedish Research Council for Health, Working Life and Welfare, Forte

Aims to contribute to increased knowledge about the life situation and health of LGBT+ people. Grants are worth up to SEK 5 million for three years.

Closing date: 25 August 2021

Further information 

 

Research grants - Nordic Cancer Union

Supports collaborative cancer research within the Nordic countries. Grants are provided for one year but may be renewed to last up to three years.

Closing date: 21 September 2021

Further information 

 

Hilda och Alfred Erikssons pris 2022

Kungl. Vetenskapsakademien inbjuder till nominering för Hilda och Alfred Erikssons pris.

Signerat skriftligt motiverat förslag önskas senast den 1 oktober 2021.

Vänligen se bifogad inbjudan och nomineringsblankett.

European calls
 

**New deadline** Marie Skłodowska-Curie Actions (MSCA) Upcoming Postdoctoral Fellowships 2021

The opening date for the MSCA 2021 Postdoctoral Fellowships program is delayed and will open on June 22, 2021. The postdoc fellow applies together with an identified Principal Investigator for a 2-year European fellowship or a 3-year Global Fellowship which has a mandatory return phase to Europe.

Closing date: 12 October 2021 (new deadline)

KI information for the call

Further information 

 

**New opening date** Marie Skłodowska-Curie Actions (MSCA) Upcoming Doctoral Networks 2021 (former ITN)

The opening date for the MSCA 2021 Postdoctoral Fellowships program is delayed and will open on June 22, 2021. A Consortium applies for a training program for PhD students. The MSCA Doctoral Networks program includes training networks, Industrial Doctorates and Joint Doctorates.

Closing date: 16 November 2021

Further information 

 

ERC-2021-AdG Advanced Grants -- Horizon Europe: Excellent Science, EU and other funders

These support established, leading principal investigators who want long-term funding to pursue a ground-breaking, high-risk project. Applicants should be exceptional leaders in terms of originality and significance of their research contributions, with a track record of significant research achievements in the last ten years.  Applications may be made in any field of research, with an emphasis on the frontiers of science, scholarship and engineering.

Advanced Grants may be awarded up to €2.5 million for a period of 5 years, though an additional € 1 million can be made available under certain circumstances.

If you are interested in applying for an ERC Advanced Grant with KI as host institution, please contact KI Grants Office for further information.

Closing date: 31 August 2021

Further information 

 

Postdoctoral grants in the Calmette and Yersin programme

Institut Pasteur, FR

The Institut Pasteur invites applications for its postdoctoral grants within the Calmette and Yersin programme. This enables researchers to conduct a postdoctoral traineeship at an institute within the Institut Pasteur international network. Topics include research into infectious diseases and public health activities.

Applicants must hold a PhD and the grant must be performed outside the applicants’ work country, home country and the country in which their university studies were conducted. Applicants who have already begun their postdoctoral traineeship are not eligible. Candidates from all nationalities may apply.

Grants are worth up to €1,900 per month to cover living expenses and insurance over two years.

Closing date:  9 July 2021

Further information 

 

Individual research grants
 

Wings for Life, GB

The Wings for Life Spinal Cord Research Foundation invites executive summaries for its individual research grants. These support basic and clinical research into spinal cord injury with the perspective to improve outcomes. Projects may be in the following areas:

  • basic research projects – nerve regeneration, plasticity, neuronal and glial protection, functional deficits induced by lesions, preferentially in mammalian models and on mechanisms present in humans;
  • clinical research projects – spinal cord injury management, other areas related to traumatic spinal cord injury essential to the propagation of neurological and functional recovery.

Proposals should have a view to translation from laboratory to clinical setting and have the potential to provide real benefits to human patients.

Postdoctoral researchers, PhD students and technicians may apply.

Grants cover the recipients’ salary for up to three years and are worth up to €57,000 per year for postdoctoral applicants, €34,000 for PhD students and €21,000 for technicians.

Award amount max €171,000

Closing date: 1 September 2021 (Forecast)

Further information 

 

EIC transition – challenge driven call
Horizon Europe: Innovative Europe, BE and other funders

The European Innovation Council, under Horizon Europe: Innovation Europe, invites proposals for its EIC transition – challenge driven call. This aims to leverage results of an ongoing or recently finished pathfinder, FET flagship or European Research Council proof of concept project in specific challenge areas and push forward groundbreaking innovations with a clear perspective towards market uptake for specific applications. The challenge areas are:

  • medical technology and devices – from lab to patient;
  • energy harvesting and storage technologies.

Activities should mature a technology beyond the experimental proof of principle in laboratory and develop the business case for the market uptake of the technology in an innovation for a specific application or set of applications that address the objectives of the challenge. The outcome should be a technology that is demonstrated to be effective, together with a business model and business plan for its development to market.

Proposals may be submitted by a single entity established in a member state or associated country if they are an SME or research performing organisation, or a small consortium of between two and five independent legal entities that may include universities, research organisations, SMEs or larger companies, user or customer organisations or potential end users.

The total budget is worth €40.5 million. Requests of up to €2.5m are considered appropriate, but larger amounts may be requested if justified. Funding is provided at 100 per cent of eligible costs. Funded applicants are also eligible to receive additional grants worth up to €50,000 to undertake portfolio activities.

Award amount max €2,500,000

Closing date: 22 September 2021

Further information 

US calls                                                                                                                                                                                                          

Federal Funding agencies

Understanding and reducing cardiovascular disease in type 1 diabetes mellitus (R01 – clinical trial optional), NIH

This funding opportunity is intended to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease among individuals with Type 1 Diabetes Mellitus (T1DM) and advances the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM.   

Deadline: October 15, 2021, by 5:00 PM local time of applicant organization. Letter of Intent Due Date: 30 days prior to the application due date.

Funding Opportunity Announcement (FOA): RFA-HL-21-014

Further information: RFA-HL-21-014: Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional) (nih.gov)

 

Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed), NIH

The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection. It will not support the collection of new data.

Deadline: October 28, 2021, February 26, 2022, October 28, 2022. All applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-20-078

Further information: PAR-20-078: Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed) (nih.gov)

 

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional), NIH

This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Deadline: November 08, 2021, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-21-190

Further information: PAR-21-190: Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) (nih.gov)

 

Ethical Issues in Translational Science Research (R01 Clinical Trial Optional), NIH

The purpose of this Funding Opportunity Announcement is to support research to address ethical issues in translational science research. Collaboration between bioethicists, legal scholars, social scientists, and translational research scientists is encouraged. The focus is to develop knowledge to inform the ethical development, modification, or application of novel findings, technologies, and approaches to improve human health, including their impact on individuals, families, communities, and society.

Examples of areas where ethics research could inform translational research include, but are not limited to:

  • Ethical issues associated with general and personalized synthetic biology; integrated and complex organoids; tissue chip platforms; iPS cells; and human-animal chimeras
  • Studies that explore the ethical and societal challenges of medical use of machine learning, artificial intelligence, machine intelligence, and algorithmic medicine
  • Ethical issues associated with data collection, de-identification, ownership, licensing, data sharing, data access, data integration, data mining, data repurposing from perspective of data providers, data users, and society
  • Ethical implications of development and use of gene editing, genomic editing, gene drive for discovery, therapeutic, preventive, enhancement, and societal purposes
  • Individual, community, and societal impact of development, implementation, and use of personalized and precision research and medicine, including but not limited to, issues of access, equity, autonomy, or justice
  • Ethical challenges of innovative research project designs, collaborations, business models for conduct and implementation of translational research among diverse stakeholders
  • Ethical issues in translational research across privacy/confidentiality/transparency/security spectrum impacting individuals, communities, entrepreneurs, industry, society; gaps and needs related to current regulatory models
  • Ethical issues in translational research in development and implementation of behavior change/modification at individual, community, and society level

Deadline: October 6, 2021, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-TR-20-001

Further information: RFA-TR-20-001: Ethical Issues in Translational Science Research (R01 Clinical Trial Optional) (nih.gov)

 

Foundations
 

CFF/NIH-unfunded award, Cystic Fibrosis Foundation, US

The Cystic Fibrosis Foundation invites applications for its CFF/NIH-unfunded award. This supports cystic fibrosis-related research projects that have been submitted to and approved by the National Institutes of Health, but cannot be supported by available NIH funds.

Eligibility: Applications must have been submitted to NIH as an R01/R21 and fall within the upper 40th percentile or to governmental funding agencies in other countries with an NIH R01/R21-equivalent funding programme that provides reviewer critiques and a report indicating the application scored in the upper 40th percentile.

Budget: Awards are worth up to USD 125,000 per year for up to two years. Indirect costs are not allowed.

Deadline: December 31, 2021 by 5 p.m. ET.

Further information: CFF/NIH R01/R21-Unfunded Award | CF Foundation

 

New investigator grant programme, BrightFocus Foundation, US

BrightFocus Foundation invites letters of intent for its new investigator grant programme. This research grant is intended to support investigators during their early years as an independent investigator involved in studies that have an impact on the causes and/or treatment of macular degeneration.

Budget: $150,000 per year (total value $450,000), up to 3 years

Deadline: Letter of Intent deadline: July 29, 2021, 5:00 PM EST; Full Proposal deadline: December 3, 2021, 05:00 PM EST (By Invitation only)

Further information 

 

Innovative research grants, BrightFocus Foundation, US

The BrightFocus Foundation invites applications for its innovative research grants. This program is intended to provide support for high-risk/high-gain age-related macular degeneration research. It hopes to attract established investigators to apply for this support, but the aims of the application must contain outside-the-box ideas that are novel in the field. Applicants who are experts in another field are encouraged to apply their talents to proposing innovative research in the macular degeneration field.

Budget: $200,000 per year (total value $600,000) up to 3 years

Deadline: Letter of Intent deadline: July 29, 2021, 5:00 PM EST; Full Proposal deadline: December 3, 2021, 05:00 PM EST (By Invitation only)

Further information